Quite an expensive settlement, but a settlement
26/06/20 -"We have taken into account the guided cash out in 2020 and 2021 for the announced settlements of the three litigations. Regarding the 15% tax shield Bayer also guided for, we remain rather more ..."
Pages
73
Language
English
Published on
26/06/20
You may also be interested by these reports :
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...
15/09/26
At a time when Novartis and AstraZeneca nurse a run of late-stage R&D setbacks, GSK’s recent clinical trial successes for oncology candidates, ...
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...